Рынок кожных аллергопроб в США переходит к этапу стандартизации и контроля качества

09-07-2026 03:37 PM CET | Health & Medicine Press release from: DataM intelligence 4 Market Research LLP September 2026: U.S. skin allergy testing is entering a more disciplined purchasing cycle. The challenge is no longer access to a prick-test device or allergen panel; it is whether hospitals and allergy practices can reproduce the same clinically useful result across operators, extract lots and testing locations. According to DataM Intelligence, the global Skin Allergy Testing Market reached US$617.31 million in 2024 and is projected to reach US$1,136.83 million by 2033, growing at a CAGR of 7.1% during 2025-2033. Prick testing accounted for 42.81% of the market in 2024, while North America held 43.17%. Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/skin-allergy-testing-market?kailas ## FDA Regulation Makes the Test System More Important Than the Applicator U.S. skin prick testing sits at the intersection of medical-device and biologic regulation. FDA classifies allergen-delivery needles used for skin prick and intradermal testing as Class II medical devices subject to 510(k) review. The allergenic extracts placed on the skin are separately regulated by FDA's Center for Biologics Evaluation and Research. FDA distinguishes standardized extracts, where potency can be determined lot by lot against an established standard, from non-standardized extracts. That distinction matters operationally. An apparently standardized testing workflow can still generate variability through the applicator, penetration depth, extract characteristics, measurement technique and operator interpretation. FDA's March 2026 approval of standardized grass-pollen extracts from Jubilant HollisterStier reinforces why reagent standardization remains strategically important. Eight grass-pollen extracts are specifically indicated for skin-test diagnosis as well as immunotherapy. ## False Results Carry a Clinical Cost Beyond Repeat Testing The highest-cost error is not simply repeating a test. FDA requires food-allergen diagnostic extracts to carry a warning about anaphylaxis following false-negative skin-test results. The action followed post-market reports involving false-negative peanut testing, some associated with life-threatening reactions after later exposure. FDA advises that negative findings may require confirmation through serum-specific IgE testing or medically supervised oral food challenge when clinical suspicion remains high. False positives create a different burden: unnecessary avoidance, additional testing and potentially incorrect attribution of symptoms. The issue is amplified because all food-allergen extracts currently licensed by FDA for diagnostic use are non-standardized, meaning no U.S. potency standard exists for those products. This makes extract provenance, lot consistency, controls and documented interpretation rules legitimate supplier-qualification criteria rather than laboratory details. ## Digital Measurement Is Attacking the Most Manual Part of Prick Testing Manual wheal interpretation remains one of the clearest sources of variability. A 2026 prospective study involving 100 pediatric patients compared ruler measurements with digital calipers. Inter-observer differences averaged 0.03 mm with digital calipers versus 0.22 mm with rulers, supporting more consistent measurement through digital tools. AI is moving one step further. A 2025 Nature Communications study evaluated an AI-assisted readout system for an automated skin prick platform using thousands of wheals. The algorithm achieved 98.4% specificity and 85.0% sensitivity for positive-versus-negative classification in its validation cohort. Physicians adjusted 5.8% of AI measurements, but those changes altered interpretation in only 0.5% of cases. The system also reduced inter- and intra-observer variability and reading time. This points to a commercially meaningful digital-health opportunity: computer-assisted measurement supporting-not replacing-clinical interpretation. Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/skin-allergy-testing-market?kailas ## Hospitals Need Throughput Without Sacrificing Controls Provider capacity is becoming part of the purchasing equation. AAAAI, ACAAI and the National Medical Association issued a joint call in May 2026 to strengthen the U.S. allergy and immunology workforce and improve access, particularly in underserved areas. Skin testing therefore needs to become easier to standardize across nurses, technicians and physicians. Digital measurement, structured templates and automatic transfer into the electronic health record can reduce repetitive work. AAAAI already identifies EHR data transfer, standardization, remote-monitoring tools and mobile health applications as useful components of modern allergy-practice infrastructure. The strongest technology proposition is consequently not the device with the largest allergen panel. It is the workflow capable of delivering repeatable placement, controlled timing, objective measurement, documented positive/negative controls and structured results that can move directly into the clinical record. ## 2026 Reimbursement Changes Add Another Layer to Site-of-Care Economics Medicare economics are also changing. ACAAI's analysis of the 2026 Physician Fee Schedule shows revised practice-expense methodology and different financial effects between facility and non-facility services. Allergy testing, immunotherapy, and other common allergy procedures are directly affected by RVU-based reimbursement. That reinforces the importance of throughput economics. Testing systems must be compared on staff time, patients tested per session, consumables, extract waste, repeat-test frequency, and documentation burden-not purchase price alone. Hospital systems with multiple allergy locations gain an additional benefit from standardized platforms: easier training, common protocols and more comparable results across sites. Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=skin-allergy-testing-market?kailas Additional Benefits: ✅ Get Interactive Dashboard Access (With No Additional Cost) ✅ Three months of analyst support to answer queries related to the report. ## Reproducibility Becomes the Supplier-Qualification Benchmark The strongest U.S. supplier positions through 2033 will combine FDA-compliant applicators, reliable extract sourcing, objective measurement, digital documentation, and sufficient service support to reproduce the same testing protocol across a distributed clinical network. Stallergenes Greer and ALK provide important allergenic-extract and skin-testing benchmarks; Jubilant HollisterStier demonstrates the value of standardized extracts; Thermo Fisher's specific-IgE testing ecosystem illustrates the complementary laboratory pathway used when clinical history and skin-test findings require additional clarification. The commercial shift is therefore from selling prick-test components toward building a validated allergy-diagnostic workflow with known sources of variability under control. DataM Intelligence analyzes the market across prick, patch and intradermal testing and hospitals, specialist clinics, diagnostic laboratories and other end users. Contact Us: Sai Kiran Business Development Manager DataM Intelligence 4market Research LLP 6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] About DataM Intelligence DataM Intelligence is a market research and consulting firm providing syndicated research, customized intelligence, competitive analysis, and strategic advisory across healthcare and medical-device markets. Its research supports regulatory pathway assessment, supplier qualification, clinical workflow analysis, technology benchmarking, partner identification, and commercialization strategy through decision-focused industry intelligence. This release was published on openPR. Permanent link to this press release: Copy Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release. You can edit or delete your press release Skin Allergy Testing Market to Reach US$1.14 Billion by 2033 as U.S. Hospitals Reprice Prick Testing Around Reproducibility and Digital Readout here News-ID: 4623913 • Views: … 09-07-2026 | Health & Medicine DataM intelligence 4 Market Research LLP Automated Compounding Devices Market Size to Reach USD 6.19 Billion by 2033 as I … The global market is expected to grow from USD 2.93 billion in 2026 to USD 6.19 billion by 2033, registering a CAGR of 11.4% during 2026-2033. The market is gaining attention as hospitals and pharmacies seek safer, more consistent and efficient ways to prepare customized medications, intravenous solutions and parenteral nutrition. They are used across IV compounding, oral liquid compounding, total parenteral nutrition and chemotherapy preparation. The automated compounding devices … 09-07-2026 | Health & Medicine DataM intelligence 4 Market Research LLP Continuous Glucose Monitoring Devices Market to Reach US$10.72 Billion by 2033 a … TOKYO, Japan - September 2026: Continuous glucose monitoring is entering a more demanding commercialization phase in Japan. The purchasing question is shifting from whether CGM improves glucose visibility to whether sensor economics, accuracy, software reliability, and clinical workflow can support wider routine use without creating an unsustainable recurring cost. According to DataM Intelligence, the global Continuous Glucose Monitoring Devices Market reached US$6.06 billion in 2025 and is projected to reach … 09-07-2026 | Health & Medicine DataM intelligence 4 Market Research LLP Drug Delivery Devices Market to Reach US$151.41 Billion by 2033 as U.S. Hospital … Texas, USA - September 2026: U.S. drug-delivery investment is moving upstream-from purchasing finished devices toward selecting platforms while medicines are still being developed. Oncology is particularly exposed to this shift as biologics, targeted medicines, and other complex therapies create requirements around injection volume, viscosity, dose accuracy, administration setting, and patient monitoring. According to DataM Intelligence, the global Drug Delivery Devices Market reached US$95.73 billion in 2025 and is projected to … 09-07-2026 | Health & Medicine DataM intelligence 4 Market Research LLP Oncology Companion Diagnostics Market Size to Reach USD 13.09 Billion by 2035 as … According to DataM Intelligence, the global oncology companion diagnostics market size was valued at USD 5.48 billion in 2025 and is projected to reach USD 13.09 billion by 2035, registering a CAGR of 9.1% during 2026-2035. The market is increasing as cancer care moves toward treatment decisions based on specific biomarkers and molecular characteristics. The oncology companion diagnostics market forecast remains favorable as laboratories and healthcare providers adopt next-generation sequencing, … All 5 Releases 04-22-2026 | Food & Beverage Fujian Lixing Food Co., Ltd. FDA vs Non-FDA Freeze-Dried Fruit Suppliers: Risk and Market Access Differences FDA Freeze-Dried Fruit Suppliers vs Non-FDA Approved Producers: Risk and Market Access Differences Fujian Lixing Food Co., Ltd. - an internationally acclaimed provider of FDA freeze dried fruits and a pioneer in vacuum sublimation technology - today provided an insightful analysis that illuminated critical differences between FDA-registered suppliers and non-approved producers; with rising consumer demand for "clean label" healthy snacks a must, this study illustrates why regulatory compliance must be adhered … 11-07-2023 | Health & Medicine DreaMed Diabetes DreaMed receives 5th FDA Clearance TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes … 05-27-2019 | Health & Medicine CAS DataLoggers FDA Compliant Blood Storage and Preservation Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility … 03-08-2017 | Health & Medicine Procenius Consulting New FDA Design Control Training Courses Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a … 01-31-2017 | Science & Education GRC Training Solutions fda online training GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet … 11-09-2016 | Science & Education GRCTS FDA online training Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding …